Skip to main content

Advertisement

SpringerLink
Log in

Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Objectives

Based on a novel paclitaxel–resveratrol drug matrix, the safety and efficacy to inhibit intimal hyperplasia were studied in symptomatic claudicants with morphologically challenging lesions.

Background

The treatment of peripheral artery occlusive disease (PAOD) with percutaneous transluminal angioplasty is limited by occurrence of vessel recoil and neointimal hyperplasia. Drug-coated balloons (DCB) deliver drugs to the arterial wall to potentially reduce the restenosis rate. A number of paclitaxel-coated balloon technologies are available to treat peripheral lesions.

Methods

In this randomized controlled trial, a total of 153 patients with symptomatic PAOD in femoro-popliteal lesions were randomized either to DCB or plain old balloon angioplasty (POBA).

Results

The mean lesion length was 13.2 ± 10.4 cm with target lesion total occlusions in 26.1% of all patients (40/153). The primary endpoint of in-lesion late lumen loss (LLL) at 6 months was significantly reduced in the DCB group as compared to the POBA group (0.35 mm CI [0.19; 0.79 mm] vs. 0.72 mm CI [0.68; 1.22 mm], p = 0.006). At 12 months, the TLR rate in the DCB group was significantly lower as compared to the POBA group (17.8 vs. 37.7% p = 0.008). The censored walking distance increase suggests a benefit for patients who underwent DCB angioplasty as compared to the standard POBA treatment (12 months 165 ± 105 vs. 94 ± 136 m, p = 0.012).

Conclusion

The use of paclitaxel–resveratrol-matrix-coated peripheral balloon angioplasty as compared to POBA was associated with significantly reduced in-lesion LLL and reduced TLR rates.

ClinicalTrials.gov identifier NCT01970579.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Diehm C, Allenberg JR, Pittrow D, et al. German epidemiological trial on ankle brachial index study group. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053–61.

    Article  PubMed  Google Scholar 

  2. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–40.

    Article  PubMed  Google Scholar 

  3. Schillinger M, Minar E. Claudication: treatment options for femoropopliteal disease. Prog Cardiovasc Dis. 2011;54(1):41–6.

    Article  PubMed  Google Scholar 

  4. Albrecht T, Speck U, Baier C, et al. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. Invest Radiol. 2007;42(8):579–85.

    Article  CAS  PubMed  Google Scholar 

  5. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwälder U, Beregi JP, Claussen CD, Oldenburg A, Scheller B, Speck U. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–99.

    Article  CAS  PubMed  Google Scholar 

  6. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118(13):1358–65.

    Article  CAS  PubMed  Google Scholar 

  7. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5(6):831–40.

    Article  CAS  PubMed  Google Scholar 

  8. Laird JR, Schneider PA, Tepe G, et al. IN.PACT SFA trial investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–38.

    Article  PubMed  Google Scholar 

  9. Rosenfield K, Jaff MR, White CJ, et al. LEVANT 2 investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145-53. Cardiol. 2015;66(21):2329-38.

  10. Katsanos K, Kitrou P, Spiliopoulos S, Diamantopoulos A, Karnabatidis D. Comparative effectiveness of plain balloon angioplasty, bare metal stents, drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery disease: systematic review and Bayesian network meta-analysis of randomized controlled trials. J Endovasc Ther. 2016;23(6):851–63.

    Article  PubMed  Google Scholar 

  11. Giacoppo D, Cassese S, Harada Y, Colleran R, Michel J, Fusaro M, Kastrati A, Byrne RA. Drug-coated balloon versus plain balloon angioplasty for the treatment of femoropopliteal artery disease: an updated systematic review and meta-analysis of randomized clinical trials. JACC Cardiovasc Interv. 2016;9(16):1731–42.

    Article  PubMed  Google Scholar 

  12. Katsanos K, Spiliopoulos S, Paraskevopoulos I, Diamantopoulos A, Karnabatidis D. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23(2):356–70.

    Article  PubMed  Google Scholar 

  13. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11(1):13–23.

    Article  CAS  PubMed  Google Scholar 

  14. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–9.

    Article  PubMed  Google Scholar 

  15. Schroeder H, Meyer DR, Lux B, et al. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86(2):278–86.

    Article  PubMed  Google Scholar 

  16. Scheinert D, Schulte KL, Zeller T, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14–21.

    Article  PubMed  Google Scholar 

  17. Jia X, Zhang J, Zhuang B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the acoart I trial. JACC Cardiovasc Interv. 2016;9(18):1941–9.

    Article  PubMed  Google Scholar 

  18. Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1 Pt A):102–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Dr. Bettina Kelsch, Dr. Maren Kutschera and Dr. Ines Gemeinhardt at InnoRa Berlin, Germany, for their respective efforts in conducting and monitoring this trial. We also wish to acknowledge Dr. Ralf Degenhardt at the Herzkreislaufzentrum Rotenburg, Germany, for his statistical support and Denny Herberger at Medical Scientific Affairs B.Braun, Berlin, for his logistic contributions. Finally, our thanks are extended to the members of our critical event committee consisting of Prof. Vorwerk (Klinikum Ingolstadt), Prof. Gebauer (Charité Berlin) and Dr. Fiedler (Harzklinikum Wernigerode).

Funding

All study participants received funding from B.Braun per included patient within a milestone-based system.

Author information

Authors and Affiliations

  1. Department of Radiology, RoMed Klinikum Rosenheim, Pettenkoferstr. 10, 83022, Rosenheim, Germany

    Gunnar Tepe

  2. Department of Radiology and Interventional Radiology, Vivantes Hospital Berlin Neukölln, Berlin, Germany

    Özlem Gögebakan & Thomas Albrecht

  3. Departments of Radiology and Vascular Surgery, Klinikum Magdeburg, Magdeburg, Germany

    Ulf Redlich & Jörg Tautenhahn

  4. Departments of Radiology and Vascular Surgery, University Hospital Magdeburg, Magdeburg, Germany

    Jens Ricke & Zuhir Halloul

  5. Department of Diagnostic and Interventional Radiology, Hubertus Hospital, Berlin, Germany

    Dirk-Roelfs Meyer

  6. Medical Scientific Affairs, B. Braun Melsungen AG, Berlin, Germany

    Matthias Waliszewski

  7. Charité Universitätsmedizin, Berlin, Germany

    Beatrix Schnorr

  8. University Heart Center Bad Krozingen, Bad Krozingen, Germany

    Thomas Zeller

  9. Diakonissenanstalt zu Flensburg, Flensburg, Germany

    Stefan Müller-Hülsbeck

  10. Heart Center Munich, Munich, Germany

    Ilka Ott

Authors
  1. Gunnar Tepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Özlem Gögebakan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulf Redlich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jörg Tautenhahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jens Ricke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zuhir Halloul
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dirk-Roelfs Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Matthias Waliszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Beatrix Schnorr
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thomas Zeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stefan Müller-Hülsbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ilka Ott
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Thomas Albrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gunnar Tepe.

Ethics declarations

Conflict of interest

GT and TA have lectured and received research grants from B.Braun. MW is a full-time employee of Medical Scientific Affairs department of B.Braun Melsungen AG.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tepe, G., Gögebakan, Ö., Redlich, U. et al. Angiographic and Clinical Outcomes After Treatment of Femoro-Popliteal Lesions with a Novel Paclitaxel-Matrix-Coated Balloon Catheter. Cardiovasc Intervent Radiol 40, 1535–1544 (2017). https://doi.org/10.1007/s00270-017-1713-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-017-1713-2

Keywords

Search

Navigation